Insights On Drug Discovery

  1. Integrated Drug Discovery: Hit To PCC In 16 Months 5/8/2026

    Accelerate your drug discovery program with integrated, cross-functional expertise that advances promising candidates from hit identification to preclinical development with speed and efficiency.

  2. ADC Development Grows More Complex — SPR Insights Bring Clarity 4/14/2026

    Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.

  3. Mammalian Cell Line Development 3/26/2026

    Explores how modern cell line engineering boosts speed, stability, and scalability across biologics, with practical insights to cut risk and improve readiness for downstream development.

  4. WuXia293Stable: Express What CHO Can't 3/26/2026

    Discover a modern 293‑based expression system built for higher purity, controlled glycosylation, and improved activity, offering a new option for teams developing complex or next‑generation biologics.

  5. What Matters More In DNA-Encoded Libraries? 3/16/2026

    DELs can screen billions of compounds, but library quality determines meaningful results. See how thoughtful design shapes early decisions that influence which drug candidates move forward.

  6. Translating Massive Data Into Therapeutic Momentum 3/13/2026

    New advances in chemomics, proteome mapping, and modern synthetic methods are redefining how quickly and precisely discovery teams can move from raw data to meaningful clinical momentum.

  7. ADCs: Overcoming Analytical Challenges In Next-Gen Cancer Therapies 2/24/2026

    Antibody-Drug Conjugates (ADCs) represent a revolutionary approach in cancer treatment. But with innovation comes complexity. 

  8. What FDA CRLs Reveal About E&L 2/18/2026

    FDA feedback shows E&L gaps still delay approvals. This preview flags common issues — from unknown compounds to weak tox data — and offers ways to strengthen E&L approaches and cut regulatory risk.

  9. From Promise To Patients: Smarter Pathways To Scale In Cell And Gene Therapy Manufacturing 2/12/2026

    As the field evolves, the strategies developers choose may prove just as influential as the therapies themselves in determining how quickly innovation reaches patients.

  10. The Science Of Cell Line Development For Biologics 2/12/2026

    Selecting and engineering the right cell line is not simply a technical milestone; it is a strategic decision that shapes cost of goods, development timelines, and the overall probability of success.